Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Pulmatrix is raising $8,070,723.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Teofilo Raad played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pulmatrix

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily respirable and emitted), represents a new paradigm in inhaled drug delivery based on unique properties: dense, high drug load engineered particles with highly efficient dispersibility and delivery to the airways. The iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance.

To learn more about Pulmatrix, visit http://www.pulmatrix.com/

Contact:
Teofilo Raad, Chief Executive Officer
781-357-2333
traad@pulmatrix.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved